DOCSLIB.ORG

United States Patent (19) [11] 3,968,111 Bach Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
United States Patent (19) [11] 3,968,111 Bach Et Al United States Patent (19) [11] 3,968,111 Bach et al. (45) July 6, 1976 54 8,8-DISUBSTITUTED-6- 3,113,133 12/1963 Hofmann et al..w. 260/285.5 METHYLERGOLINES AND RELATED COMPOUNDS Primary Examiner-Alton D. Rollins 75) inventors: Nicholas J. Bach; Edmund C. Assistant Examiner-Mary Vaughn Kornfeld, both of Indianapolis, Ind. Attorney, Agent, or Firm-James L. Rowe, Everet F. 73) Assignee: Eli Lilly and Company, Indianapolis, Smith Ind. 22 Filed: Dec. 6, 1974 21 Appl. No.: 530,320 57 ABSTRACT 8,8-Disubstituted-6-methylergolines and 9-ergolenes, 52 U.S. Cl............................... 260/285.5; 424/261 prepared by alkylation of lysergic, isolysergic or their 51 int. C.’................ C07D 457/02; C07D 457/10 9,10-dihydro analogues, optionally followed by chemi 58) Field of Search.................................. 260/285.5 cal modification of an 8-substituent. 56 References Cited UNITED STATES PATENTS 9 Claims, No Drawings 2,86,074 1 1/1958 Kornfeld et al.................. 260/285.5 3,968, 111 1 2 1722 (1957) prepared the 8-methyl derivative of D-iso 8,8-DISUBSTITUTED-6-METHYLERGOLINES AND lysergic acid diethylamide, stating that they were, how RELATED COMPOUNDS ever, unable to obtain substitution at C8 using dihydro lysergic acid methyl ester and the alkylating agent used BACKGROUND OF THE INVENTION successfully with lysergic acid itself; to wit, methylio Compounds based on the ergoline ring system dide and potassium amide. These authors also prepared 8-ethyl-D-isolysergic acid diethylamide and the 1,8- dimethyl-D-isolysergic acid diethylamide. There is no mention in the literature of an 8,8-disubstituted-9-ergo O lene in which the substituents at 8 are other than amide groups and in which the 1-position is not substituted. 6-Methyl-8,8-disubstituted ergolines are not mentioned in the literature. 5 SUMMARY OF THE INVENTION This invention provides compounds of the formula R R 20 R. have a suprising variety of pharmaceutical activities. R For example, lysergic and isolysergic acid are 8-car -CH3 boxy-6-methyl-9-ergolenes. The amides of lysergic acid, many of which have valuable and unique pharma cologic properties, include the naturally occurring oxy 25 2. tocic alkaloids - ergocornine, ergokryptine, ergono N vine, ergocristine, ergosine, ergotamine, etc. - and synthetic oxytocics such as methergine, as well as the HN synthetic hallucinogen - lysergic acid diethylamide or LSD. The corresponding amides of 6-methyl-8-carbox 30 wherein R is alk, carbo(C-ca) alkoxy, Cl or Br; yergoline, known generically as dihydroergot alkaloids, R" is carboxyl, carbo(Cr-cs) alkoxy, or CH2, are oxytocic agents of lower potency and also lower wherein alk is (C-C)alkyl snf toxicity than the ergot alkaloids themselves. Recently, Z is H, OH, CN, OSO-alk, Y-phenyl, or Y-alk, it has been found by Clemens, Semonsky, Meites and wherein Y is S or O; and their various co-workers, that many ergot-related drugs 35 R'' and R' when taken singly are H; and, when have activity as prolactin inhibitors including ergocor taken together with the carbon atoms to which they nine, dihydroergocornine, 2-bromo-o-ergokryptine are attached, form a double bond. and d-6-methyl-8-cyanomethylergoline. References Also included within the scope of this invention are embodying some of the newer findings in this field of pharmaceutically-acceptable acid addition salts of ergoline pharmacology are the following: Nagasawa 40 compounds according to Formula 1 formed with a and Meites, Proc. Soc. Exp'tl. Biol. Med, 135, 469 non-toxic acid. These pharmaceutically-acceptable (1970); Lutterbeck et al., Brit. Med. J., 228, (July 24, salts include salts derived from inorganic acids such as: 1971); Heuson et al., Europ. J. Cancer, 353 (1970); hydrochloric acid, nitric acid, phosphoric acid, sulfuric Col. Czech, Chen. Commun., 33,577 (1968); Nature, acid, hydrobromic acid, hydriodic acid, nitrous acid, 221, 666 (1969); Seda et al., J. Reprod. Fert., 24, 263 45 phosphorous acid and the like, as well as salts derived (1971); Mantle and Finn, id, 441; Semonsky and co from nontoxic organic acids such as aliphatic mono and workers, Col. Czech. Chen. Conn., 36, 2200 (1971); dicarboxylic acids, phenyl-substituted alkanoic acids, Schaar and Clemens, Endocr.,90, 285-8 (1972); Clem hydroxyalkanoic and alkandioic acids, aromatic acids, ens and Schaar, Proc. Soc. Exp. Biol. Med., 139, aliphatic and aromatic sulfonic acids, etc. Such phar 659-662 (1972) and Sweeney, Clemens, Kornfeld and 50 maceutically-acceptable salts thus include sulfate, Poore, 64th Annual Meeting, American Association pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phos Cancer Research, April, 1973. Recently issued patents phate, monohydrogenphosphate, dihydrogenphos in the field of erogoline derivatives or lysergic acid phate, metaphosphate, pyrophosphate, chloride, bro derivatives include the following: U.S. Pat. No. mide, iodide, fluoride, acetate, propionate, decanoate, 3.704,233, U.S. Pat. No. 3,709,891, U.S. Pat. No. 55 caprylate, acrylate, formate, isobutyrate, caprate, hep 3,585,201, U.S. Pat. No. 3,666,762, U.S. Pat. No. tanoate, propiolate, oxalate, malonate, succinate, su 3,586,683, U.S. Pat. No. 3,717,640, and U.S. Pat. No. berate, sebacate, fumarate, maleate, mandelate, 3,592,816. - butyne-1,4-dioate, hexyne-1,6-dioate, benzoate, chlo Only a few 8,8-disubstituted ergolines have been robenzoate, methylbenzoate, dinitrobenzoate, hydrox prepared. A majority of these compounds also have a 60 ybenzoate, methoxybenzoate, phthalate, terephthalate, substituent on the indole nitrogen thus yielding a 1,8,8- benzenesulfonates, toluenesulfonate, chlorobenzene tri-substituted derivative. For example, Baker et al. sulfonate, xylenesulfonate, phenylacetate, phenylpro publishing in Molecular Pharmacology, 9, 23 (1973) pionate, phenylbutyrate, citrate, lactate, 3-hydroxybu reported 1,8-dimethyl-D-lysergic acid p-bromanilide. tyrate, glycolate, malate, tartrate, methanesulfonate, This compound showed no hallucinogenic activity un 65 propanesulfonate, naphthalene-1-sulfonate, naphtha like D-lysergic acid p-bromanilide. The same com lene-2-sulfonate and the like salts. pound is mentioned in Science, 178, 614 (1972). In the above formula, (C-C)alkyl includes the Troxler and Hofmann, Helvetica Chemica Acta, 40, groups methyl, ethyl, propyl, and isopropyl. The term 3,968,111 3 4 (C-C3)alkoxy thus includes the terms methoxy, eth oxy, and propoxy and the term carbo(C-C)alkoxy includes the terms carbomethoxy, carboethoxy, carbo COO at R (CH2) -- propoxy and carboisopropoxy. In the above formula, when R'' and R'' are hydrogen, the compound is de R nominated an ergoline, but when R'' and R', when taken together with a carbon atom to which they are attached, form a double bond, the compound is denom -CH2 inated a 9-ergolene. The following compounds exem plify the scope of our invention: O D-6-methyl-8o-ethyl-8cy-carbomethoxyergoline sul fate D-6-methyl-8o-isopropyl-8ps-chloroergoline phos phate D-8o-isopropyl lysergic acid 15 D-8a-ethyl lysergic acid D-8o-ethyl dihydrolysergic acid D-83-methylisolysergic acid A strong non-hydrolytic base such as sodium amide, D-6-methyl-86-ethyl-8o-carbo-n-propoxy-9-ergo potassium amide, lithium tetramethylpiperidide, potas lene maleate 20 sium diisopropyl amide and the like are used to replace D-6-methyl-86-hydroxymethyl-8a-ethyl-9-ergolene the hydrogen at Cs to form an anion, which anion then succinate reacts with the alkylating agent R' (CH).X. Com D-6-methyl-8g-cyanomethyl-8o-carboethoxy-9- pounds according to formula I above in which R is ergolene carboxyl are prepared by hydrolyzing the correspond D-6-methyl-8o-cyanomethyl-8p-n-propylergoline 25 ing carbo (C-C) alkoxy compound. Compounds in hydrochloride which R' is CHZ wherein Z is hydroxyl are prepared D-6-methyl-86-mesyloxymethyl-8-a-bromoergoline by lithium aluminum hydride reduction of the corre tartrate sponding ester grouping. Compounds in which Z is D-6-methyl-8o-methoxymethyl-8g-carboethoxyer cyanide are prepared by first forming the mesylate goline citrate 30 ester of the hydroxymethyl derivative (compounds D-6-methyl-8g-ethoxymethyl-8o-carboisopropoxy wherein R' is CHZ and Z is OH) and then replacing 9-ergolene lactate the mesylate radical with cyanide by use of sodium D-6-methyl-8-a-phenoxymethyl-8g-carbomethoxyer cyanide. Compounds in which Z is Y-phenyl or Y-alk goline methane sulfonate D-6-methyl-86-phenoxymethyl-8o-carboethoxy-9- 35 are prepared in similar fashion by reacting the mesylate ergolene ester with phenol or phenylmercaptan, a lower alkanol D-8a-phenylmercaptomethyl lysergic acid or a lower alkylmercaptan. Finally, compounds in D-8a-methylmercaptomethyl lysergic acid toluene which R is Cl or Br and R' is carboCC-C)alkoxy are sulfonate prepared by reacting the alkali metal salt of a lysergic, D-86-n-propylmercaptomethyl isolysergic acid, 40 dihydrolysergic or isolysergic acid corresponding and the like. The compounds of this invention are white thereto with p-toluenesulfonylchloride, p-toluenesul crystalline solids, as are their acid addition salts formed fonylbromide or other acyl chloride or bromide. In this with non-toxic acids. Compounds in which one of R or reaction, suprisingly, the ester group does not replace R" is carbo(C-C)alkoxy, are prepared by alkylating the anion but the halogen atom. 45 It will be apparent to those skilled in the art from the an ester of lysergic or isolysergic acid or of dihydroly above general directions that individual combinations sergic or dihydroisolysergic acid with an alkylating of substituents for RandR' can be achieved by altering agent of the formula R' (CH),X wherein R' is the order in which reactions are carried out involving a CH, CN-CH or carbo(C-C)alkoxy group after the initial reaction with the alkylating agent, R'(CH).X. 50 This invention is further, illustrated by the following C-O-alk, specific examples.
Load more

Recommended publications
  • Ergot Alkaloids Mycotoxins in Cereals and Cereal-Derived Food Products: Characteristics, Toxicity, Prevalence, and Control Strategies
    agronomy Review Ergot Alkaloids Mycotoxins in Cereals and Cereal-Derived Food Products: Characteristics, Toxicity, Prevalence, and Control Strategies Sofia Agriopoulou Department of Food Science and Technology, University of the Peloponnese, Antikalamos, 24100 Kalamata, Greece; [email protected]; Tel.: +30-27210-45271 Abstract: Ergot alkaloids (EAs) are a group of mycotoxins that are mainly produced from the plant pathogen Claviceps. Claviceps purpurea is one of the most important species, being a major producer of EAs that infect more than 400 species of monocotyledonous plants. Rye, barley, wheat, millet, oats, and triticale are the main crops affected by EAs, with rye having the highest rates of fungal infection. The 12 major EAs are ergometrine (Em), ergotamine (Et), ergocristine (Ecr), ergokryptine (Ekr), ergosine (Es), and ergocornine (Eco) and their epimers ergotaminine (Etn), egometrinine (Emn), egocristinine (Ecrn), ergokryptinine (Ekrn), ergocroninine (Econ), and ergosinine (Esn). Given that many food products are based on cereals (such as bread, pasta, cookies, baby food, and confectionery), the surveillance of these toxic substances is imperative. Although acute mycotoxicosis by EAs is rare, EAs remain a source of concern for human and animal health as food contamination by EAs has recently increased. Environmental conditions, such as low temperatures and humid weather before and during flowering, influence contamination agricultural products by EAs, contributing to the Citation: Agriopoulou, S. Ergot Alkaloids Mycotoxins in Cereals and appearance of outbreak after the consumption of contaminated products. The present work aims to Cereal-Derived Food Products: present the recent advances in the occurrence of EAs in some food products with emphasis mainly Characteristics, Toxicity, Prevalence, on grains and grain-based products, as well as their toxicity and control strategies.
    [Show full text]
  • Ergot Alkaloid Biosynthesis in Aspergillus Fumigatus : Association with Sporulation and Clustered Genes Common Among Ergot Fungi
    Graduate Theses, Dissertations, and Problem Reports 2009 Ergot alkaloid biosynthesis in Aspergillus fumigatus : Association with sporulation and clustered genes common among ergot fungi Christine M. Coyle West Virginia University Follow this and additional works at: https://researchrepository.wvu.edu/etd Recommended Citation Coyle, Christine M., "Ergot alkaloid biosynthesis in Aspergillus fumigatus : Association with sporulation and clustered genes common among ergot fungi" (2009). Graduate Theses, Dissertations, and Problem Reports. 4453. https://researchrepository.wvu.edu/etd/4453 This Dissertation is protected by copyright and/or related rights. It has been brought to you by the The Research Repository @ WVU with permission from the rights-holder(s). You are free to use this Dissertation in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you must obtain permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/ or on the work itself. This Dissertation has been accepted for inclusion in WVU Graduate Theses, Dissertations, and Problem Reports collection by an authorized administrator of The Research Repository @ WVU. For more information, please contact [email protected]. Ergot alkaloid biosynthesis in Aspergillus fumigatus: Association with sporulation and clustered genes common among ergot fungi Christine M. Coyle Dissertation submitted to the Davis College of Agriculture, Forestry, and Consumer Sciences at West Virginia University in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Genetics and Developmental Biology Daniel G. Panaccione, Ph.D., Chair Kenneth P. Blemings, Ph.D. Joseph B.
    [Show full text]
  • United States Patent
    Patented Aug. 17, 1948 2,447,214 UNITED STATES PATENT OFF ICE 2,447,214 OPTICALLY ACTIVE SALTS OF THE LY SERGIC AND SOLYSERGIC ACD DE RVATIVES AND A PROCESS FOR, THER PREPARATION AND SOLATION Arthur Stoll and Albert Hofmann, Basel, Switzer land, assignors to Sandoz Ltd., Fribourg, Swit zerland, a Swiss firm No Drawing. Application August 23, 1943, Serial No. 499,714. In Switzerland September 16, 1942 16 Claims. (CI. 260-236) 2 The preparation and the isolation of the thera The synthetically prepared derivatives of the peutically valuable and active derivatives con lysergic acid which also correspond to the above tained in ergot is a problem that has occupied cited formula possess also the same lability as chemistry and pharmacy for more than 120 years. the natural lysergic acid derivatives. Their is0 Actually it is known that the action of ergot is 5 lation and preparation encounters the same dif due to the alkaloids contained therein, which have ficulties as in the case of the lysergic acid hydra been isolated in recent years and which are zides C15H15N2CONHNH2 (made according to U. S. always present as pairs of isomers. Chrono Letters Patent 2,090,429) and in the case of the logically the following alkaloids have become alkaloids of the type of ergobasine, which can be 0 prepared by partial synthesis and in which the known up to noW: lysergic acid is combined with an amine in form Ergotinine (1875). Ergotoxine (1906) of an acid amide (see U. S. Letters Patent No. Ergotamine (1918) Ergotaminine (1918) 2,090,430).
    [Show full text]
  • Risk Assessment of Argyreia Nervosa
    Risk assessment of Argyreia nervosa RIVM letter report 2019-0210 W. Chen | L. de Wit-Bos Risk assessment of Argyreia nervosa RIVM letter report 2019-0210 W. Chen | L. de Wit-Bos RIVM letter report 2019-0210 Colophon © RIVM 2020 Parts of this publication may be reproduced, provided acknowledgement is given to the: National Institute for Public Health and the Environment, and the title and year of publication are cited. DOI 10.21945/RIVM-2019-0210 W. Chen (author), RIVM L. de Wit-Bos (author), RIVM Contact: Lianne de Wit Department of Food Safety (VVH) [email protected] This investigation was performed by order of NVWA, within the framework of 9.4.46 Published by: National Institute for Public Health and the Environment, RIVM P.O. Box1 | 3720 BA Bilthoven The Netherlands www.rivm.nl/en Page 2 of 42 RIVM letter report 2019-0210 Synopsis Risk assessment of Argyreia nervosa In the Netherlands, seeds from the plant Hawaiian Baby Woodrose (Argyreia nervosa) are being sold as a so-called ‘legal high’ in smart shops and by internet retailers. The use of these seeds is unsafe. They can cause hallucinogenic effects, nausea, vomiting, elevated heart rate, elevated blood pressure, (severe) fatigue and lethargy. These health effects can occur even when the seeds are consumed at the recommended dose. This is the conclusion of a risk assessment performed by RIVM. Hawaiian Baby Woodrose seeds are sold as raw seeds or in capsules. The raw seeds can be eaten as such, or after being crushed and dissolved in liquid (generally hot water).
    [Show full text]
  • Bromocriptine-A Changing Scene
    LONDON, SATURDAY 20 DECEMBER 1975 Br Med J: first published as 10.1136/bmj.4.5998.667 on 20 December 1975. Downloaded from MEDICAL JOURNAL Bromocriptine -a changing scene Ergot, known to man since ancient times, is a product of the Levodopa has been used to lower prolactin levels, but its fungus Claviceps purpurea that grows on rye and grain. A action does not last long enough; bromocriptine has a much symposium' at the Royal College of Physicians last May longer action and is therefore more effective. reviewed the pharmacology and clinical uses of the older as Since bromocriptine has been shown not to be teratogenic it well as the more recently introduced ergot compounds. All the has been used recently in restoring fertility. Its place has still ergot alkaloids are derivatives of lysergic acid: the best known finally to be defined, but it appears to be effective not only in are the oxytocic ergometrine and the mixed ao-adrenergic patients with hyperprolactinaemia but also in some with agonist and antagonist ergometrine compounds. Nevertheless, normal prolactin levels, as described by M 0 Thorner et al,14 the first group of ergot compounds isolated by Barger, Carr, at p 694 of this issue. There is, however, some danger in and Dale in 1906, and called ergotoxine,2 is a mixture of ergot restoring fertility in women with small pituitary tumours, alkaloids: ergocornine, ergocristine, and ergokryptine. since such lesions may rapidly enlarge, with visual impairment, The inhibition oflactation by ergot was described by Dodart3 during pregnancy. Arguably the tumour should be irradiated in 1676.
    [Show full text]
  • Albert Hofmann's Pioneering Work on Ergot Alkaloids and Its Impact On
    BIRTHDAY 83 CHIMIA 2006, 60, No. 1/2 Chimia 60 (2006) 83–87 © Schweizerische Chemische Gesellschaft ISSN 0009–4293 Albert Hofmann’s Pioneering Work on Ergot Alkaloids and Its Impact on the Search of Novel Drugs at Sandoz, a Predecessor Company of Novartis Dedicated to Dr. Albert Hofmann on the occasion of his 100th birthday Rudolf K.A. Giger* and Günter Engela Abstract: The scientific research on ergot alkaloids is fundamentally related to the work of Dr. Albert Hofmann, who was able to produce, from 1935 onwards, a number of novel and valuable drugs, some of which are still in use today. The complex chemical structures of ergot peptide alkaloids and their pluripotent pharmacological activity were a great challenge for Dr. Hofmann and his associates who sought to unravel the secrets of the ergot peptide alkaloids; a source of inspiration for the design of novel, selective and valuable medicines. Keywords: Aminocyclole · Bromocriptine Parlodel® · Dihydroergotamine Dihydergot® · Dihydro ergot peptide alkaloids · Ergobasin/ergometrin · Ergocornine · Ergocristine · α- and β-Ergocryptine · Ergolene · Ergoline · Ergoloid mesylate Hydergine® · Ergotamine Gynergen® · Ergotoxine · Lisuride · Lysergic acid diethylamide LSD · Methylergometrine Methergine® · Methysergide Deseril® · Paspalic acid · Pindolol Visken® · Psilocybin · Serotonin · Tegaserod Zelmac®/Zelnorm® · Tropisetron Navoban® Fig. 1. Albert Hofmann in 1943, 1979 and 2001 (Photos in 2001 taken by J. Zadrobilek and P. Schmetz) Dr. Albert Hofmann (Fig. 1), born on From the ‘Ergot Poison’ to *Correspondence: Dr. R.K.A. Giger January 11, 1906, started his extremely Ergotamine Novartis Pharma AG NIBR Global Discovery Chemistry successful career in 1929 at Sandoz Phar- Lead Synthesis & Chemogenetics ma in the chemical department directed The scientific research on ergot alka- WSJ-507.5.51 by Prof.
    [Show full text]
  • Phoretic Analysis of Ergot Alkaloids. Relations Mobility in the Cle Vine
    Acta Pharm, Suecica 2, 357 (1965) Thin-layer chromatographic and thin-layer electro- phoretic analysis of ergot alkaloids.Relations between structure, RM value and electrophoretic mobility in the cle vine series STIG AGUREll DepartMent of PharmacOgnosy, Kunql, Farmaceuliska Insiitutei, StockhOLM, Sweden SUMMARY A thin-layer chromatographic and electrophoretic study of the ergot alkaloids has been made, to find rapid methods for the separation and identification of the known ergot alkaloids. The mobilities of ergot alkaloids in several useful chromatographic and electrophore- tic systems are recorded. Relations have been observed between structure and R" value in methanol-chloroform on Silica Gel G. A simple, rapid thin-layer electrophoretic technique has been de- vised for separation of ergot alkaloids, and a relation between structure and electrophoretic mobility is evident. Two-dimensional combinations of thin-layer chromatography and thin-layer electro- phoresis and chromatography are described. Numerous paper chromatographic procedures have been published for separation of the ergot alkaloids and their derivatives. Hofmann (1) and Genest & Farmilio (2) have recently listed these systems. The general advantages of thin-layer chromatography (TLC) over paper partition chromatography are well known: shorter time of equilibration and devel- opment, generally better resolution, smaller amounts of substance rc- quired, and wider choice of reagents. Several reports of TLC of ergot alkaloids have been published. In gene- ral, these investigations (2-6 and others) have dealt 'with limited groups of alkaloids, or with a specific problem involving at most a dozen of the 40 now known naturally occurring ergot alkaloids. Some paper chromate- .357 graphic systems using Iorrnamide-treated papers have also been adopted for thin-layer chromatographic use (7, 8).
    [Show full text]
  • Diversification of Ergot Alkaloids in Natural and Modified Fungi
    Toxins 2015, 7, 201-218; doi:10.3390/toxins7010201 OPEN ACCESS toxins ISSN 2072-6651 www.mdpi.com/journal/toxins Review Diversification of Ergot Alkaloids in Natural and Modified Fungi Sarah L. Robinson and Daniel G. Panaccione * Division of Plant and Soil Sciences, West Virginia University, Morgantown, WV 26506, USA; E-Mail: [email protected] * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +1-304-293-8819; Fax: +1-304-293-2960. Academic Editor: Christopher L. Schardl Received: 21 November 2014 / Accepted: 14 January 2015 / Published: 20 January 2015 Abstract: Several fungi in two different families––the Clavicipitaceae and the Trichocomaceae––produce different profiles of ergot alkaloids, many of which are important in agriculture and medicine. All ergot alkaloid producers share early steps before their pathways diverge to produce different end products. EasA, an oxidoreductase of the old yellow enzyme class, has alternate activities in different fungi resulting in branching of the pathway. Enzymes beyond the branch point differ among lineages. In the Clavicipitaceae, diversity is generated by the presence or absence and activities of lysergyl peptide synthetases, which interact to make lysergic acid amides and ergopeptines. The range of ergopeptines in a fungus may be controlled by the presence of multiple peptide synthetases as well as by the specificity of individual peptide synthetase domains. In the Trichocomaceae, diversity is generated by the presence or absence of the prenyl transferase encoded by easL (also called fgaPT1). Moreover, relaxed specificity of EasL appears to contribute to ergot alkaloid diversification. The profile of ergot alkaloids observed within a fungus also is affected by a delayed flux of intermediates through the pathway, which results in an accumulation of intermediates or early pathway byproducts to concentrations comparable to that of the pathway end product.
    [Show full text]
  • Impact of Ergot Alkaloid and Estradiol 17B on Whole-Body Protein Turnover and Expression of Mtor Pathway Proteins in Muscle of Cattle
    University of Kentucky UKnowledge Theses and Dissertations--Animal and Food Sciences Animal and Food Sciences 2020 Impact of Ergot Alkaloid and Estradiol 17B on Whole-Body Protein Turnover and Expression of mTOR Pathway Proteins in Muscle of Cattle Taylor Dawn Ferguson University of Kentucky, [email protected] Author ORCID Identifier: https://orcid.org/0000-0001-6598-4133 Digital Object Identifier: https://doi.org/10.13023/etd.2020.459 Right click to open a feedback form in a new tab to let us know how this document benefits ou.y Recommended Citation Ferguson, Taylor Dawn, "Impact of Ergot Alkaloid and Estradiol 17B on Whole-Body Protein Turnover and Expression of mTOR Pathway Proteins in Muscle of Cattle" (2020). Theses and Dissertations--Animal and Food Sciences. 122. https://uknowledge.uky.edu/animalsci_etds/122 This Master's Thesis is brought to you for free and open access by the Animal and Food Sciences at UKnowledge. It has been accepted for inclusion in Theses and Dissertations--Animal and Food Sciences by an authorized administrator of UKnowledge. For more information, please contact [email protected]. STUDENT AGREEMENT: I represent that my thesis or dissertation and abstract are my original work. Proper attribution has been given to all outside sources. I understand that I am solely responsible for obtaining any needed copyright permissions. I have obtained needed written permission statement(s) from the owner(s) of each third-party copyrighted matter to be included in my work, allowing electronic distribution (if such use is not permitted by the fair use doctrine) which will be submitted to UKnowledge as Additional File.
    [Show full text]
  • Ergot Alkaloids: a Review on Therapeutic Applications
    European Journal of Medicinal Plants 14(3): 1-17, 2016, Article no.EJMP.25975 ISSN: 2231-0894, NLM ID: 101583475 SCIENCEDOMAIN international www.sciencedomain.org Ergot Alkaloids: A Review on Therapeutic Applications Niti Sharma 1* , Vinay K. Sharma 1, Hemanth Kumar Manikyam 1 1,2 and Acharya Bal Krishna 1Patanjali Natural Coloroma Pvt. Ltd, Haridwar, Uttarakhand - 249404, India. 2University of Patanjali, Haridwar, Uttarakhand - 249402, India. Authors’ contributions This work was carried out in collaboration between all authors. Authors NS and VKS designed the study, wrote the first draft of the manuscript. Authors ABK and HKM supervised the study. All authors read and approved the final manuscript. Article Information DOI: 10.9734/EJMP/2016/25975 Editor(s): (1) Marcello Iriti, Professor of Plant Biology and Pathology, Department of Agricultural and Environmental Sciences, Milan State University, Italy. Reviewers: (1) Nyoman Kertia, Gadjah Mada University, Indonesia. (2) Robert Perna, Texas Institute of Rehabilitation Research, Houston, TX, USA. (3) Charu Gupta, AIHRS, Amity University, UP, India. Complete Peer review History: http://sciencedomain.org/review-history/14283 Received 28 th March 2016 Accepted 12 th April 2016 Review Article st Published 21 April 2016 ABSTRACT Ergot of Rye is a plant disease caused by the fungus Claviceps purpurea which infects the grains of cereals and grasses but it is being used for ages for its medicinal properties. All the naturally obtained ergot alkaloids contain tetracyclic ergoline ring system, which makes them structurally similar with other neurotransmitters such as noradrenaline, dopamine or serotonin. Due to this structure homology these alkaloids can be used for the treatment of neuro related conditions like migraine, Parkinson’s disease etc.
    [Show full text]
  • Introduction to the Pharmacology of Ergot Alkaloids and Related Compounds As a Basis of Their Therapeutic Application
    CHAPTER I Introduction to the Pharmacology of Ergot Alkaloids and Related Compounds as a Basis of Their Therapeutic Application B. BERDE and E. STURMER "Truth is rarely pure and never simple" OSCAR WILDE This chapter, rather unorthodox for a volume of the Handbook of Experimental Pharmacology, is not intended as a summary of the wealth of information accumu- lated in this book. It is an attempt at a compact synopsis to help those teaching pharmacology or writing a textbook of pharmacology not to overlook the essential chemical and biological basis of the therapeutically most important compounds and those of their activities which are believed to be relevant for their therapeutic effects. The present volume, entitled Ergot Alkaloids and Related Compounds, deals with chemical entities containing the tetracyclic ergolene- or ergoline-ring system. They can be obtained by extraction of different strains of the fungus cIaviceps- grown on rye or cultivated in fermentation tanks-or alternatively by partial or total synthesis. These compounds can be divided into four main structural groups: cIavine alkaloids, lysergic acids, simple lysergic acid-amides, and peptide alkaloids. One example of each type of molecule is given in Figure 1. The degree of oxidation is a criterion for further differentiation in the group of cIavine alkaloids, all of which are compounds of minor biological importance. The naturally occurring lysergic acids are divided into compounds with a double bond in the 8-9 position (8-ergolenes) and in the 9-10 position (9-ergolenes). All congeners are methylated in position (i. The two asymmetric carbon atoms in position 5 and 10 (in the case of 8-ergolenes) or 5 and 8 (in the case of Glavine-Alkaloids Lysergic Acid group Lysergic Acid Amides Peptide-Alkaloids of Alkaloids Examples: I'_ GOOH I"'" NH'GH3 b ~HN Elymoclavine D-Lysergic Acid Ergometrine Ergotamine Fig.
    [Show full text]
  • Biotechnology and Genetics of Ergot Alkaloids
    Appl Microbiol Biotechnol (2001) 57:593–605 DOI 10.1007/s002530100801 MINI-REVIEW P. Tudzynski · T. Correia · U. Keller Biotechnology and genetics of ergot alkaloids Received: 28 May 2001 / Received revision: 8 August 2001 / Accepted: 17 August 2001 / Published online: 20 October 2001 © Springer-Verlag 2001 Abstract Ergot alkaloids, i.e. ergoline-derived toxic me- tions in the therapy of human CNS disorders. Chemical- tabolites, are produced by a wide range of fungi, pre- ly the ergot alkaloids are 3,4-substituted indol deriva- dominantly by members of the grass-parasitizing family tives having a tetracyclic ergoline ring structure (Fig. 1). of the Clavicipitaceae. Naturally occurring alkaloids like Based on their complexity, they can be divided into two the D-lysergic acid amides, produced by the “ergot fun- families of compounds. In the D-lysergic acid deriva- gus” Claviceps purpurea, have been used as medicinal tives, a simple amino alcohol or a short peptide chain agents for a long time. The pharmacological effects of (e.g. ergotamine) is attached to the ergoline nucleus in the various ergot alkaloids and their derivatives are due amide linkage via a carboxy group in the 8-position. In to the structural similarity of the tetracyclic ring system the simpler clavine alkaloids (e.g. agroclavine) that car- to neurotransmitters such as noradrenaline, dopamine or boxy group is replaced by a methyl or hydroxymethyl to serotonin. In addition to “classical” indications, e.g. mi- which attachment of side groups such as in the amide- graine or blood pressure regulation, there is a wide spec- type alkaloids is not possible.
    [Show full text]